Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol
Authors:
- 28 October 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (12) , 3297-3305
Abstract
Background and objectives: Carbapenem-resistant Enterobacterales (CRE) that do not produce carbapenemases (non-CPE) are increasingly reported worldwide and represent a major therapeutic challenge. These strains are typically resistant to carbapenems due to the combined effects of ESBL and/or AmpC production and reduced outer membrane permeability. However, data on their susceptibility to new antibiotics and β-lactam/β-lactamase inhibitor (BL/BLI) combinations remain limited. This study aimed to evaluate the in vitro activity of new antibiotics and BL/BLI combinations against CR non-CPE isolates. Methods: MICs of ceftazidime–avibactam, cefepime–enmetazobactam, cefepime–taniborbactam, cefepime–zidebactam, imipenem–relebactam, meropenem–vaborbactam, aztreonam–avibactam, and cefiderocol were determined by the broth microdilution for 151 CR non-CPE isolates collected between 2024 and January 2025 at the French National Reference Center. The collection included ESBL producers (n = 33), AmpC producers (n = 79), and ESBL/AmpC co-producers (n = 29). Results: Overall susceptibility rates were as follows: cefepime–zidebactam (97.4%), aztreonam–avibactam (92.7%), ceftazidime–avibactam (91.4%), meropenem–vaborbactam (91.3%), imipenem–relebactam (88.7%), cefiderocol (86.8%), cefepime–taniborbactam (82.1%), and cefepime–enmetazobactam (68.9%). Susceptibility varied according to the resistance mechanisms. Among ESBL producers, CTX-M-33-producing strains exhibited higher MICs than CTX-M-15 producers. Among AmpC producers, no specific high-risk AmpC type was associated with higher MICs, but Klebsiella aerogenes isolates exposed higher MICs than Enterobacter cloacae complex isolates. Conclusions: CR non-CPE exhibit heterogeneous resistance profiles, especially in ESBL/AmpC co-producers and CTX-M-33-producing isolates. While cefepime–zidebactam, imipenem–relebactam, and cefiderocol were the most active agents, susceptibility testing remains essential to guide therapy in this emerging and neglected bacterial group.Keywords
Funding Information
- Advanz Pharma
This publication has 29 references indexed in Scilit:
- In-vitro activity of cefepime/enmetazobactam against extended spectrum beta-lactamases and/or ampC producing Enterobacterales and Pseudomonas aeruginosa collected across IndiaDiagnostic Microbiology and Infectious Disease, 2025
- ‘In vitro activity of cefepime-enmetazobactam on carbapenem-resistant gram negatives’—author's responseClinical Microbiology and Infection, 2025
- Cefiderocol susceptibility testing: the challenge of disc diffusionClinical Microbiology and Infection, 2025
- In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negativesClinical Microbiology and Infection, 2024
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort studyThe Lancet Infectious Diseases, 2020
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative BacilliDrugs, 2019
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosisThe Lancet Infectious Diseases, 2018
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor CombinationDrugs, 2013
- Detection of CTX-M-15 and CTX-M-33, a novel variant of CTX-M-15, in clinical Escherichia coli isolates in GreeceInternational Journal of Antimicrobial Agents, 2007